Commentary on “Preventive percutaneous coronary intervention versus optimal medical therapy alone for the treatment of vulnerable atherosclerotic coronary plaques (PREVENT): a multicenter, open-label, randomized controlled trial”. (2024). Bleeding, Thrombosis and Vascular Biology, 3(2). https://doi.org/10.4081/btvb.2024.141